Nottingham University Hospitals NHS Trust
Nottingham, NG7 2UH, United Kingdom
NCT Number: NCT05251467
Development of a new patient reported outcome measure (PROM) that will measure the daily burden of gastrointestinal symptoms over the previous 24 hour period for people with cystic fibrosis.
Looking for future studies?
Notify Me12 year and older
All sexes
Observational
Nottingham, NG7 2UH, United Kingdom
Development of a Patient Reported Outcome Measure (PROM) in line with FDA guidance. The PROM is intended for daily use to measure the symptom burden of gastrointestinal symptoms for people with CF over the last 24 hours.
Potential participant's will be identified through 6 UK CF care centres at Nottingham University Hospitals NHS Trust (paediatric and adult CF centres), Leeds Teaching Hospital NHS Trust, Manchester University NHS Foundation trust, Royal Brompton and Harefield NHS Foundation Trust and Kings College Hospital NHS Foundation Trust. In addition, recruitment for the survey and trialing the PROM on a smartphone app will also take place via social media and is therefore also open to people with CF from outside these CF centres.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Focus group to confirm PROM conceptual framework
Patient interviews to refine possible questions for the PROM
Online questionnaire to evaluate the proposed questions as part of PROM development in a larger population
Daily testing of the pilot PROM in a smartphone app for 2 weeks
Time frame: 2 years
Development of a new PROM following FDA guidance which will measure the daily impact and burden of gastrointestinal symptoms for people with CF. The recall period will be the previous 24 hours. The name of the PROM will be decided as part of the development process. Question development will be iterative. Floor and ceiling effects for each of the questions will be assessed. The CFAbd score will be used to assess construct validity of the newly developed PROM. This will be completed alongside the PROM on days 1 and day 14.
Time frame: 2 years
Adherence data - Percentage of completed PROM days over the 14 day period. Percentage of completed CFabd scores on days 1 and 14. This data will be collated through the research portal feedback facility in the app.
Time frame: 2 years
Attrition rate over the 2 weeks, define as people completing the app for two weeks (at least 10 out of 14 days) as a percentage of those initially who gave consent to take part and use the app.
Time frame: 2 years
Usability of the app - participant feedback via the app on days 7 and 14 to include questions of ease of data entry on the app, whether they experience any technical issues with the app and whether questions are meaningful to participants. These questions will be developed as part of the PROM development process.
Nottingham University Hospitals NHS Trust
Other
Acronym: CARDS-CF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05253859
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Nottingham, United Kingdom
View Trial DetailsNCT05054582
COVID-19, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Innsbruck, Tyrol, Austria
View Trial DetailsNCT02717650
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Melbourne, Victoria, Australia
View Trial DetailsNCT02950883
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Aurora, Colorado, United States
View Trial Details